Ionis priced ZANVASTRO at $285,000 a dose. Can the first Alexander disease drug build a viable ultra-rare franchise?
FDA approval has transformed zilganersen from an experimental antisense programme into the first disease-modifying medicine for Alexander disease. For Ionis Pharmaceuticals, however, ZANVASTRO is also a test of whether years of RNA-targeted neurology research can translate into a sustainable independently commercialized franchise.
